Document Detail


Use of recombinant erythropoietin in treatment of the anemia of prematurity.
MedLine Citation:
PMID:  1793163     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The anemia of prematurity is defined by a progressive decline in hemoglobin level occurring over the first 2 months of life. Unlike term newborns whose "physiologic anemia" rarely if ever necessitates any treatment, preterm infants may become anemic enough to have clinical symptoms that indicate a need for red blood cell transfusions. Various factors contribute to the development of this anemia. Some of these factors, such as the short life span of erythrocytes in preterm infants, increased sensitivity of the erythrocytes to oxidative injury, and the blood losses caused by repeated phlebotomies, would normally be expected to induce corrective reticulocytosis. Characteristically, however, this anemia is hyporegenerative. Thus, it is associated with relative reticulocytopenia, low serum erythropoietin levels, and bone marrow erythroid hypoplasia. The recent availability of recombinant human erythropoietin has opened new perspectives in the management of a variety of anemias. Based on current knowledge of the regulation and pathophysiology of fetal and neonatal erythropoiesis, recombinant erythropoietin may represent a logical and efficient alternative to giving red blood cell transfusions in the treatment of the anemia of prematurity. Clinical trials have been initiated in several countries using different approaches and methodology. At this early stage these trials do not yet fully affirm that recombinant erythropoietin can be used as the first-line therapy in infants with the anemia of prematurity. Our own observations, however, suggest that this agent is well tolerated by preterm infants and may exert a corrective effect on the anemia of prematurity.
Authors:
D S Halpérin
Related Documents :
2040933 - Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-con...
11275033 - Nucleated red blood cells in meconium aspiration syndrome.
20528363 - Palivizumab in preventing respiratory syncytial virus-related hospitalization in high-r...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The American journal of pediatric hematology/oncology     Volume:  13     ISSN:  0192-8562     ISO Abbreviation:  Am J Pediatr Hematol Oncol     Publication Date:  1991  
Date Detail:
Created Date:  1992-04-02     Completed Date:  1992-04-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7908071     Medline TA:  Am J Pediatr Hematol Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  351-63     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Hôpital cantonal universitaire, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Neonatal / blood,  physiopathology,  therapy*
Blood Cell Count / drug effects
Blood Transfusion
Combined Modality Therapy
Drug Evaluation
Erythropoiesis
Erythropoietin / administration & dosage,  physiology,  therapeutic use*
Hematocrit
Humans
Immunologic Factors / therapeutic use*
Infant, Newborn
Infant, Premature / blood
Infant, Premature, Diseases / blood,  physiopathology,  therapy*
Injections, Subcutaneous
Iron / blood,  deficiency
Longitudinal Studies
Pilot Projects
Recombinant Proteins / administration & dosage,  therapeutic use
Reticulocytes
Chemical
Reg. No./Substance:
0/Immunologic Factors; 0/Recombinant Proteins; 11096-26-7/Erythropoietin; 7439-89-6/Iron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sideroblastic anemia showing unique response to pyridoxine.
Next Document:  The GABAergic cerebello-olivary projection in the rat.